Genome-wide association of implantable cardioverter-defibrillator activation with life-threatening arrhythmias

• Published in: PloS one 2012-01, Vol.7 (1), p.e25387-e25387
• Main Authors: Murray, Sarah S, Smith, Erin N, Villarasa, Nikki, Nahey, Tara, Lande, Jeff, Goldberg, Harold, Shaw, Marian, Rosenthal, Lawrence, Ramza, Brian, Alaeddini, Jamshid, Han, Xinqiang, Damani, Samir, Soykan, Orhan, Kowal, Robert C, Topol, Eric J
• Format: Article
• Language: English
• Subjects: Aged; Analysis; Arrhythmia; Arrhythmias, Cardiac - genetics; Arrhythmias, Cardiac - mortality; Biology; Cardiac arrhythmia; Cardiac patients; Cardiology; Cardiovascular disease; Cardiovascular diseases; Case-Control Studies; Chromosome 13; Cohort Studies; Coronary vessels; Defibrillators; Defibrillators, Implantable; Deoxyribonucleic acid; Diabetes; DNA; DNA Copy Number Variations - genetics; EKG; Electrocardiography; Families & family life; Female; Females; Follow-Up Studies; Gene loci; Genes; Genetic diversity; Genetic factors; Genetic variance; Genetic Variation - genetics; Genome-wide association studies; Genome-Wide Association Study; Genomes; Genomics; Genotype; Genotyping; Heart attacks; Heart rate; Humans; Male; Males; Medicine; Oversampling; Patients; Phenotypes; Prostheses and implants; Science; Studies; Survival Rate
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0025387

To identify genetic factors that would be predictive of individuals who require an implantable cardioverter-defibrillator (ICD), we conducted a genome-wide association study among individuals with an ICD who experienced a life-threatening arrhythmia (LTA; cases) vs. those who did not over at least a 3-year period (controls). Most individuals that receive implantable cardioverter-defibrillators never experience a life-threatening arrhythmia. Genetic factors may help identify who is most at risk. Patients with an ICD and extended follow-up were recruited from 34 clinical sites with the goal of oversampling those who had experienced LTA, with a cumulative 607 cases and 297 controls included in the analysis. A total of 1,006 Caucasian patients were enrolled during a time period of 13 months. Arrhythmia status of 904 patients could be confirmed and their genomic data were included in the analysis. In this cohort, there were 704 males, 200 females, and the average age was 73.3 years. We genotyped DNA samples using the Illumina Human660 W Genotyping BeadChip and tested for association between genotype at common variants and the phenotype of having an LTA. We did not find any associations reaching genome-wide significance, with the strongest association at chromosome 13, rs11856574 at P = 5×10⁻⁶. Loci previously implicated in phenotypes such as QT interval (measure of the time between the start of the Q wave and the end of the T wave as measured by electrocardiogram) were not found to be significantly associated with having an LTA. Although powered to detect such associations, we did not find common genetic variants of large effect associated with having a LTA in those of European descent. This indicates that common gene variants cannot be used at this time to guide ICD risk-stratification. ClinicalTrials.gov NCT00664807.